Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Launched by ABBVIE · Feb 10, 2021
Trial Information
Current as of July 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called ABBV-951 for adults with advanced Parkinson's disease (PD). Parkinson's disease is a condition that affects the brain, causing symptoms like tremors, stiffness, and slow movement. ABBV-951 is an infusion treatment that delivers medication under the skin continuously for 96 weeks. The trial aims to see how safe this treatment is and how it affects the progression of the disease. About 130 participants from the U.S. and Australia will be involved, and they must have completed earlier studies to be eligible.
Participants in this trial can expect to have regular check-ups at a hospital or clinic, where their health will be monitored through blood tests, assessments, and questionnaires to look for any side effects and evaluate how well the treatment is working. It's important to note that being part of this study may involve more visits and requirements compared to their usual treatment. Overall, this trial is designed to gather information that could potentially improve the care for people living with Parkinson's disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Completion of the parent study, Study M15-736 or Study M20-339.
- Exclusion Criteria:
- • - Participant considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Mobile, Alabama, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Fresno, California, United States
Loma Linda, California, United States
Los Angeles, California, United States
Pasadena, California, United States
San Diego, California, United States
West Hollywood, California, United States
Aurora, Colorado, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Englewood, Colorado, United States
Washington, District Of Columbia, United States
Miami, Florida, United States
Ocala, Florida, United States
Ormond Beach, Florida, United States
Port Charlotte, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Brighton, Massachusetts, United States
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
Lawrenceville, New Jersey, United States
Lake Success, New York, United States
Raleigh, North Carolina, United States
New Albany, Ohio, United States
Tulsa, Oklahoma, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Greenville, South Carolina, United States
Port Royal, South Carolina, United States
Franklin, Tennessee, United States
Nashville, Tennessee, United States
Cypress, Texas, United States
Georgetown, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Richmond, Virginia, United States
Spokane, Washington, United States
Milwaukee, Wisconsin, United States
Liverpool, New South Wales, Australia
Westmead, New South Wales, Australia
Southport, Queensland, Australia
Adelaide, South Australia, Australia
Parkville, Victoria, Australia
Englewood, Colorado, United States
Washington, District Of Columbia, United States
Portland, Oregon, United States
Austin, Texas, United States
Dallas, Texas, United States
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials